Ryze Rx
Ryze Rx combines GLP-1 care with a large peptide and blend catalog. Actual clinician identity, product evidence, preparation details and monitoring need scrutiny before relying on its broad benefit claims.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
The breadth of the catalog makes ingredient-specific clinical review essential. A generic physician-supervised claim or pharmacy-sourcing statement does not resolve the evidence and safety questions raised by every listed peptide.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Ryze RX LLC operates a prescription-telehealth platform with weight, hormone, sexual-health and peptide offerings. Its current catalog describes injectable and oral GLP-1 products alongside many single peptides and blends. These are materially different preparations, not interchangeable examples of one established treatment.
What Ryze Rx prescribes, by goal
Weight
- SemaglutideFDA-approved
Listed by the seller; no price we hold.
- TirzepatideFDA-approved
Listed by the seller; no price we hold.
The catalog explicitly describes weekly injected semaglutide and tirzepatide, plus oral products. Its variant labels combine strength, concentration and vial-volume information that needs clarification against the actual prescription label. Do not interpret a website variant as individualized dosing instructions.
Sexual health
- PT-141 (bremelanotide)FDA-approved
Listed by the seller; no price we hold.
Longevity
- NAD+Compounding conditions apply
Listed by the seller; no price we hold.
- GlutathioneCompounding conditions apply
Listed by the seller; no price we hold.
NAD, sermorelin, GHK-Cu and other catalog products make energy, sleep, skin and aging claims. Ask which outcomes have been studied for the exact route and preparation, what remains uncertain and which conventional alternatives were considered.
Recovery
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
The peptide menu promotes BPC-157, CJC-1295/ipamorelin combinations and other blends for recovery and body composition. FDA has identified safety uncertainties for several substances appearing in that broader menu. Physician oversight does not itself establish formulation-specific clinical evidence or remove those uncertainties.
Sleep
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
Who prescribes
A licensed clinician
The public practice description names no individual prescriber or identified treating professional group. It claims a large licensed-provider network without establishing the actual person responsible for a particular prescription. No specific dispensing pharmacy is identified. Request the professional entity, clinician and pharmacy before considering an offered regimen.
The described process uses an online health assessment, physician review, monthly check-ins and ongoing messaging. An initial twenty-four-hour review claim is not a guarantee of an appointment, prescription or response to an urgent concern. Ask how the chosen medicine is monitored and how treatment is reassessed when goals or symptoms change.
Are labs required?
Monitoring is promoted, but the actual tests and allowance need confirmation
The about page promotes laboratory monitoring without specifying a universal baseline panel, repeat schedule or included patient allowance. Obtain the requirements and actual laboratory charges for the proposed prescription.
Ready to start with Ryze Rx?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
The site presents patient stories and extensive benefit descriptions, but those are not controlled evidence for each listed peptide or mixture. The FDA bulk-substance safety page discusses limited human information and potential immune-related or other risks for several of these ingredients. That is general regulatory guidance, not a claim that FDA issued Ryze a warning letter. A pharmacy-sourcing statement does not identify the actual preparation, facility or patient-specific justification. Ask the prescriber to explain those details before interpreting the catalog as a list of equally established options.
Other products and treatment claims
- MOTS-c
- On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- BPC-157
- On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- Kisspeptin
- Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes.
- CJC-1295
- On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it.
- Ipamorelin
- "Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.
- Epitalon
- On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
- DSIP
- On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025).
- TB-500
- On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- Oxytocin
- We have not yet read its FDA status, so we list no seller for it.
- KPV
- On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- AOD-9604
- On no FDA compounding list. AOD-9604 appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- Semax
- On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- Selank
- On no FDA compounding list. Selank appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
- LL-37
- On no FDA compounding list. Neither LL-37 nor cathelicidin, the family it belongs to, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025).
- 5-Amino-1MQ
- On no FDA compounding list. 5-Amino-1MQ (5-amino-1-methylquinolinium) appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025).
How it bills
The homepage gives more than one GLP-1 starting figure, while the catalog lists medication-specific variants and some longer kits. A complete comparable billing period and supplied quantity are not settled for every card. NAD and sermorelin prices also need their actual purchase period and preparation confirmed. Terms authorize automatic renewal until cancellation through support before the next renewal date. A complete prescription refund policy and universal testing allowance are not established. Obtain the selected clinical and financial agreement rather than relying on the generic no-long-contract claim.
For and against
- For: Administration formats described on catalog cards
- For: Monthly follow-up and messaging promoted
- For: Legal operator identified
- Against: Actual professional practice and pharmacy unnamed
- Against: Broad peptide claims exceed the evidence shown
- Against: Quantity and billing details require clarification
The evidence behind what it sells
- Semaglutide Side Effects: What the Wegovy Trials and Label Recorded
- Bremelanotide Side Effects: Nausea, Blood Pressure and Skin Darkening
- Glutathione Side Effects: What Injection, IV and Oral Studies Reported
- Sermorelin Side Effects: What the Trials and FDA Record Report
- Tirzepatide Side Effects: What the Zepbound Label and Trials Recorded
- Bremelanotide (PT-141): The FDA Approval and What the Trials Showed
Right for
Someone prepared to question the specific evidence, actual prescriber and pharmacy before considering a product from a broad peptide catalog.
Look elsewhere if
Someone treating testimonials, a large claimed provider network or a compounding-pharmacy statement as proof that every listed blend is established care.
Other sellers for weight
Metabolic Rx
Also prescribes Semaglutide, Tirzepatide.
DadVantage Men’s Health
Also prescribes Semaglutide, Tirzepatide.
Longevity Meds
Also prescribes Semaglutide, Tirzepatide.
Ryze Rx
Frequently asked questions
- Does a physician-reviewed catalog prove every peptide works?
- Clinical review does not substitute for human evidence about the particular ingredient, route and formulation.
- Is the FDA safety discussion a warning letter to Ryze?
- It is general guidance about bulk substances, not a provider-specific warning attributed to this business.
- Can the website variant be used as dosing instructions?
- The actual prescription and pharmacy label need to resolve the concentration, supplied amount and instructions.
Sources
- Current program, network and headline claims
- Public weight catalog and variant descriptions
- Public peptide catalog and formulation claims
- Operator and cancellation terms
- Monitoring and support claims
- FDA ingredient-specific safety uncertainties
See what Ryze Rx prescribes today
Ryze Rx sets its own prices, plans and the states it serves. Check them before you start.